PDL BioPharma Total Assets 2010-2020 | PDLI

PDL BioPharma total assets from 2010 to 2020. Total assets can be defined as the sum of all assets on a company's balance sheet.
PDL BioPharma Annual Total Assets
(Millions of US $)
2020 $0
2019 $716
2018 $964
2017 $1,243
2016 $1,215
2015 $1,012
2014 $962
2013 $544
2012 $280
2011 $269
2010 $317
2009 $338
PDL BioPharma Quarterly Total Assets
(Millions of US $)
2020-12-31 $0
2020-06-30 $521
2020-03-31 $660
2019-12-31 $717
2019-09-30 $865
2019-06-30 $890
2019-03-31 $924
2018-12-31 $964
2018-09-30 $984
2018-06-30 $946
2018-03-31 $1,100
2017-12-31 $1,243
2017-09-30 $1,224
2017-06-30 $1,302
2017-03-31 $1,238
2016-12-31 $1,215
2016-09-30 $1,216
2016-06-30 $1,049
2016-03-31 $1,055
2015-12-31 $1,012
2015-09-30 $1,021
2015-06-30 $996
2015-03-31 $1,114
2014-12-31 $962
2014-09-30 $980
2014-06-30 $916
2014-03-31 $853
2013-12-31 $544
2013-09-30 $430
2013-06-30 $401
2013-03-31 $313
2012-12-31 $280
2012-09-30 $250
2012-06-30 $260
2012-03-31 $235
2011-12-31 $269
2011-09-30 $271
2011-06-30 $284
2011-03-31 $249
2010-12-31 $317
2010-09-30 $258
2010-06-30 $272
2010-03-31 $358
2009-12-31 $338
2009-09-30 $264
2009-06-30 $218
2009-03-31 $219
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.000B $0.055B
Protein Design Labs Inc. is a biopharmaceutical company focused on the research, development and commercialization of novel therapies for inflammation and autoimmune diseases, acute cardiac conditions and cancer. PDL markets several biopharmaceutical products in the United States through its hospital sales force and wholly-owned subsidiary, ESP Pharma, Inc. As a leader in the development of humanized antibodies, PDL has licensed its patents to numerous pharmaceutical and biotechnology companies, some of which are now paying royalties on net sales of licensed products.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $165.194B 10.05
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.361B 16.35
Biohaven Pharmaceutical Holding (BHVN) United States $10.098B 0.00
Ginkgo Bioworks Holdings (DNA) United States $5.208B 0.00
Emergent Biosolutions (EBS) United States $1.617B 6.92
Arcus Biosciences (RCUS) United States $1.305B 33.09
Myovant Sciences (MYOV) United Kingdom $0.956B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.500B 0.00
Zymeworks (ZYME) Canada $0.368B 0.00
Gelesis Holdings (GLS) United States $0.349B 0.00
Ambrx Biopharma (AMAM) United States $0.154B 0.00
Enzo Biochem (ENZ) United States $0.108B 22.10
SQZ Biotechnologies (SQZ) United States $0.097B 0.00